

Dorina Belotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4248204/publications.pdf>

Version: 2024-02-01

30
papers

1,626
citations

304743

22
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

2334
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. <i>Cancer Research</i> , 2003, 63, 5224-9. | 0.9 | 241 |
| 2 | Inhibition of Angiogenesis and Murine Hemangioma Growth by Batimastat, a Synthetic Inhibitor of Matrix Metalloproteinases. <i>Journal of the National Cancer Institute</i> , 1995, 87, 293-298. | 6.3 | 220 |
| 3 | Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin. <i>Clinical Cancer Research</i> , 2004, 10, 4813-4821. | 7.0 | 144 |
| 4 | TNP-470 (AGM-1470): Mechanisms of action and early clinical development. <i>European Journal of Cancer</i> , 1996, 32, 2520-2527. | 2.8 | 108 |
| 5 | Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. <i>European Journal of Cancer</i> , 2003, 39, 1948-1956. | 2.8 | 87 |
| 6 | HOXC5 and HOXC8 Expression Are Selectively Turned on in Human Cervical Cancer Cells Compared to Normal Keratinocytes. <i>Biochemical and Biophysical Research Communications</i> , 1999, 257, 738-745. | 2.1 | 67 |
| 7 | Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion. <i>Molecular Cancer Research</i> , 2008, 6, 525-534. | 3.4 | 65 |
| 8 | Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine Mechanisms. <i>American Journal of Pathology</i> , 2014, 184, 1050-1061. | 3.8 | 56 |
| 9 | Soluble stroma-related biomarkers of pancreatic cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, . | 6.9 | 56 |
| 10 | Thrombospondin-1 promotes mesenchymal stromal cell functions via TGF β 2 and in cooperation with PDGF. <i>Matrix Biology</i> , 2016, 55, 106-116. | 3.6 | 52 |
| 11 | Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP1 and TIMP2 and tumor thrombospondin1. <i>International Journal of Cancer</i> , 2015, 136, 721-729. | 5.1 | 50 |
| 12 | Synthesis and evaluation of stereopure \pm -trifluoromethyl-malic hydroxamates as inhibitors of matrix metalloproteinases. <i>Tetrahedron Letters</i> , 2004, 45, 1611-1615. | 1.4 | 47 |
| 13 | Enhancement of Metastatic Potential of Murine and Human Melanoma Cells by Laminin Receptor Peptide G: Attachment of Cancer Cells to Subendothelial Matrix as a Pathway for Hematogenous Metastasis. <i>Journal of the National Cancer Institute</i> , 1993, 85, 235-240. | 6.3 | 44 |
| 14 | Expression of the 67 kD Laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLC5. <i>European Journal of Cancer</i> , 1996, 32, 1598-1602. | 2.8 | 39 |
| 15 | The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2). <i>Angiogenesis</i> , 2019, 22, 133-144. | 7.2 | 37 |
| 16 | Targeting angiogenesis with compounds from the extracellular matrix. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1674-1685. | 2.8 | 36 |
| 17 | Prognostic significance of laminin production in relation with its receptor expression in human breast carcinomas. <i>Breast Cancer Research and Treatment</i> , 1995, 35, 195-199. | 2.5 | 30 |
| 18 | Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. <i>British Journal of Cancer</i> , 2012, 107, 360-369. | 6.4 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies. <i>Neoplasia</i> , 2012, 14, 846-856. | 5.3 | 28 |
| 20 | Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. <i>Carcinogenesis</i> , 2019, 40, 303-312. | 2.8 | 28 |
| 21 | Alternative Vascularization Mechanisms in Tumor Resistance to Therapy. <i>Cancers</i> , 2021, 13, 1912. | 3.7 | 28 |
| 22 | Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 715-725. | 4.1 | 27 |
| 23 | CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy. <i>Cells</i> , 2020, 9, 952. | 4.1 | 23 |
| 24 | Shedding of the 67-kD laminin receptor by human cancer cells. <i>J Biol Chem</i> , 1996, 271, 226-234. | | 22 |
| 25 | Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. <i>Thrombosis and Haemostasis</i> , 2011, 106, 705-711. | 3.4 | 18 |
| 26 | Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 647-658. | 3.3 | 17 |
| 27 | Thrombospondin modulates basic fibroblast growth factor activities on endothelial cells. <i>Exp Cell Res</i> , 1992, 161, 210-213. | 1.4 | 15 |
| 28 | Stereochemically pure α -trifluoromethyl-malic hydroxamates: synthesis and evaluation as inhibitors of matrix metalloproteinases. <i>Tetrahedron</i> , 2006, 62, 10171-10181. | 1.9 | 7 |
| 29 | Apelin Resistance Contributes to Muscle Loss during Cancer Cachexia in Mice. <i>Cancers</i> , 2022, 14, 1814. | 3.7 | 3 |
| 30 | Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. <i>Matrix Biology</i> , 2021, 103-104, 22-36. | 3.6 | 2 |